Gold 2013 farmacologia clinica
-
Upload
evidenciaterapeuticacom -
Category
Documents
-
view
771 -
download
3
Transcript of Gold 2013 farmacologia clinica
![Page 1: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/1.jpg)
JORGE GUERREROResidente 1er añoMedicina Falimiar y
ComunitariaFarmacología Clínica
![Page 2: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/2.jpg)
Morbidity and mortality
aimed at immediately
relieving
reducing the impact of symptoms reducin
g the ri
sk o
f futu
re
adverse h
ealth e
vents
Focus on both the short-term and long
term impact of COPD on our patients.
![Page 3: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/3.jpg)
EPIDEMIOLOGY
11.78% (1988-1994) 15.66% (1999-2004)
14.78% (2005-2008)
Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020. Epub 2011 Mar 25
![Page 4: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/4.jpg)
DEFINITION CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Preventable Treatable
PERSISTENT
Chronic
Response not Reversible
![Page 5: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/5.jpg)
This definition does not use the terms chronic bronchitis and emphysema and excludes asthma (reversible airflow limitation).
DEFINITION CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic bronchitis, defined as the presence
of cough and sputum production for at least
3 months in each of 2 consecutive years, is
not necessarily associated with airflow
limitation.Emphysema, defined as destruction of the alveoli.
![Page 6: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/6.jpg)
SYNTOMS OF COPD
![Page 7: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/7.jpg)
CARDINAL SYNTOMS
![Page 8: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/8.jpg)
WHAT CAUSE COPD ? TABACCO SMOKERS
![Page 9: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/9.jpg)
INDOOR AIR POLLUTION
WHAT CAUSE COPD ?
Biomass fuel used for cooking and heating in poorly vented dwellings, a risk factor that particularly affects
![Page 10: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/10.jpg)
OCCUPATIONAL DUST AND CHEMICALS
WHAT CAUSE COPD ?
![Page 11: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/11.jpg)
OUTDOOR AIR POLLUTION
WHAT CAUSE COPD ?
Total burden of inhaled particles
![Page 12: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/12.jpg)
DIAGNOSIS OF COPD
![Page 13: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/13.jpg)
![Page 14: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/14.jpg)
+ SPIROMETRY (Air flow limitation)Simple test to measure the amount of air a
person can breathe out, and the amount of time taken to do so. FVC (Forced Vital Capacity): maximum volume of air
that can be exhaled during a forced maneuver. FEV1 (Forced Expired Volume in one second):
volume expired in the first second of maximal expiration after a maximal inspiration. This is a measure of how quickly the lungs can be emptied.
FEV1/FVC: FEV1 expressed as a proportion of the FVC, gives a clinically useful index of airflow limitation.
DIAGNOSIS OF COPD
![Page 15: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/15.jpg)
WHY DO SPIROMETRY FOR COPD?
Spirometry is needed to make a clinical diagnosis of COPD.
A normal value for spirometry effectively excludes the diagnosis of clinically relevant COPD.
Together with the presence of symptoms, spirometry helps gauge COPD severity and can be a guide to specific treatment steps.
![Page 16: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/16.jpg)
![Page 17: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/17.jpg)
ASSESMENT OF COPD
• Symptoms (impact on patient’s health status)
• Degree of airflow limitation (using spirometry) • Risk of exacerbations• Comorbidities
![Page 18: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/18.jpg)
ASSESS SYMTOMS
measure clinical control self administered
measures of health status91 and predicts future mortality risk
![Page 19: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/19.jpg)
mM
RCA - C
B - D
![Page 20: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/20.jpg)
ASSESMENT OF COPD
• Symptoms (impact on patient’s health status)
• Degree of airflow limitation • Risk of exacerbations• Comorbidities
![Page 21: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/21.jpg)
DEGREE OF AIR FLOW LIMITATION
![Page 22: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/22.jpg)
ASSESMENT OF COPD
• Symptoms (impact on patient’s health status)
• Degree of airflow limitation • Risk of exacerbations• Comorbidities
![Page 23: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/23.jpg)
CONCEPT. Acute event. Worsening of the patient’s respiratory symptoms. leads to a change in medication.
ASSESSMENT OF RISK OF EXACERBATIONS
The best predictor of having frequent
exacerbations
=
Previous Exacerbations2 0R MORE PER YEARGOLD 2 + Exace
rbatio
ns = G
OLD 3 0r 4
![Page 24: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/24.jpg)
ASSESMENT OF COPD
• Symptoms (impact on patient’s health status)
• Degree of airflow limitation • Risk of exacerbations• Comorbidities
![Page 25: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/25.jpg)
ASSESSMENT OF COMORBIDITIES
![Page 26: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/26.jpg)
ASSESMENT OF COPD
• Symptoms (impact on patient’s health status)
• Degree of airflow limitation • Risk of exacerbations• Comorbidities
![Page 27: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/27.jpg)
COMBINED COPD ASSESMENT
• Symptoms (impact on patient’s health status)
• Degree of airflow limitation • Risk of exacerbations• Comorbidities
![Page 28: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/28.jpg)
COMBINED COPD ASSESMENT
When assessing risk, choose the highest risk according to GOLD
grade or exacerbation history. (One or more hospitalizations
for COPD exacerbations should be considered high risk.
![Page 29: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/29.jpg)
Patient Group A – Low Risk, Less Symptoms
Typically GOLD 1 or GOLD 2 (Mild or Moderate airflow limitation) and/or 0-1 exacerbation per year and mMRC grade 0-1 or CAT score < 10
Patient Group B – Low Risk, More Symptoms
Typically GOLD 1 or GOLD 2 (Mild or Moderate airflow limitation) and/or 0-1 exacerbation per year and mMRC grade ≥ 2 or CAT score ≥ 10
![Page 30: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/30.jpg)
Patient Group C – High Risk, Less Symptoms Typically GOLD 3 or GOLD 4 (Severe or Very
Severe airflow limitation) and/or ≥ 2 exacerbations per year and mMRC grade 0-1 or CAT score < 10
Patient Group D – High Risk, More
Symptoms Typically GOLD 3 or GOLD 4 (Severe or Very
Severe airflow limitation) and/or ≥ 2 exacerbations per year and mMRC grade ≥ 2 or CAT score ≥ 10
![Page 31: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/31.jpg)
Example: Imagine a patient with a CAT score of 18, FEV1 of 55% of predicted, and a history of 3 exacerbations within the last 12 months.
![Page 32: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/32.jpg)
Example: Imagine a patient with a CAT score of 18, FEV1 of 55% of predicted, and a history of 3 exacerbations within the last 12 months.
![Page 33: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/33.jpg)
![Page 34: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/34.jpg)
TO BE CONTINUED…
![Page 35: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/35.jpg)
TRATAMIENTO
![Page 36: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/36.jpg)
ABANDONO DEL TABAQUISMO
Mayor capacidad de intervencion en la historia natural del EPOC.
Vareniclina
![Page 37: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/37.jpg)
![Page 38: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/38.jpg)
EJERCICIO CARDIOVASCULAR
![Page 39: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/39.jpg)
TRATAMIENTO FARMACOLOGICO
Reducir los sintomas.Reduce la frecuencia y severidad de las exacerbaciones.
Controla la tolerancia para el inicio del ejercicio.
![Page 40: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/40.jpg)
Terapia Individualizada.Disponibilidad del medicamento.Costo del medicamentoRespuesta por parte del paciente
TRATAMIENTO FARMACOLOGICO
Acerca de la Preescripción
![Page 41: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/41.jpg)
BRONCODILATADORES
Fundamental para el CONTROL de SÍNTOMAS
Se prefiere por vía Inhalada La escogencia entre: beta-2-agonists,
anticolinergicos, teofilina o terapia combinada…’ Los de larga acción, producen mayor tiempo,
libre de síntomas. Combinacion de broncodilatadores de clase
farmacológica diferente disminuye el riesgo de efectos secundarios.
TRATAMIENTO FARMACOLOGICO
![Page 42: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/42.jpg)
TRATAMIENTO FARMACOLOGICO
CORTICOIDES INHALADOS
Pacientes con FEV1< 60%.Tratamiento regular: Disminuye los
síntomas.Relacionados con aumento
Incidencia de Neumonía.NO usar en monoterapia.
![Page 43: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/43.jpg)
CORTICOIDES ORALES
No usar tratamiento a largo plazo con corticosteroide oral.
TRATAMIENTO FARMACOLOGICO
![Page 44: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/44.jpg)
METILXANTINAS (Bloqueo R Adenosina)
Menos efectivas y toleradas que los broncodilatadores de larga acción.
La adición de Teofilina con Salmeterol, aumento en el VEF1 y alivio de la disnea.
Bajas dosis de Teofilina disminuye los síntomas, mas no la función pulmonar.
TRATAMIENTO FARMACOLOGICO
![Page 45: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/45.jpg)
TRATAMIENTO FARMACOLOGICO
INHIBIDORES 4-P-DIESTERASA (AMPc)
Reduce las exacerbaciones en sinergismo con los corticoides orales o broncodilatadores de larga acción.
![Page 46: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/46.jpg)
TRATAMIENTO FARMACOLOGICO
AGENTES MUCOLÍTICOSPacientes con esputo viscoso, se
benefician, sin embargo los beneficios son leves.
![Page 47: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/47.jpg)
AGENTES ANTITUSIVOS
TRATAMIENTO FARMACOLOGICO
![Page 48: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/48.jpg)
Example: Imagine a patient with a CAT score of 18, FEV1 of 55% of predicted, and a history of 3 exacerbations within the last 12 months.
![Page 49: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/49.jpg)
TRATAMIENTO FARMACOLOGICO
![Page 50: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/50.jpg)
TRATAMIENTO FARMACOLOGICO
![Page 51: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/51.jpg)
OTROS TRATAMIENTOS
USO DE VACUNAS
![Page 52: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/52.jpg)
OTROS TRATAMIENTOS
PaO2 menor (55 mmHg) or SaO2 88%,
con o sin hipercapnia confirmada dos
veces en un periodo de 3 semanas.
PaO2 entre (55 mmHg) y (60 mmHg), o
SaO2 of 88%, con evidencia de HTP,
edema periferico sugestivo de ICC, o
policitemia (hematocrito > 55%).
![Page 53: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/53.jpg)
EXACERBACIONES
![Page 54: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/54.jpg)
![Page 55: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/55.jpg)
![Page 56: Gold 2013 farmacologia clinica](https://reader031.fdocuments.us/reader031/viewer/2022012916/5562ba98d8b42a09618b4a4c/html5/thumbnails/56.jpg)